Genmab
From Wikipedia, the free encyclopedia
| Genmab A/S | |
|---|---|
 |
|
| Type | Public (OMX: GEN) |
| Founded | 1999 |
| Headquarters | Copenhagen, Denmark |
| Key people | Lisa Drakeman (President and CEO), Michael Widmer (Chairman of the board) |
| Industry | Biotechnology |
| Products | Pharmaceuticals, antibodies |
| Revenue | DKK 529.5 million (2007)[1] |
| Profit | ▼ (DKK 383.4 million) (2007)[1] |
| Employees | 291 (2007)[1] |
| Website | www.genmab.com |
Genmab A/S (OMX: GEN) is a Danish pharmaceutical company, founded in February 1999 and based in Copenhagen. Internationally, it operates through the subsidiaries Genmab BV in Utrecht, The Netherlands, Genmab Ltd in Stevenage, United Kingdom Genmab, Inc in Princeton, New Jersey, USA, and is publicly traded on the OMX Nordic Exchange and the OMX Copenhagen 20.[2] Genmab, Inc recently expanded with an antibody manufacturing facility in Brooklyn Park, Minnesota, USA.
[edit] Research Pipeline
Status of major offerings in Genmab's research pipeline, as of late 2007.[3]
| Name | Indications | Status | Collaborations |
|---|---|---|---|
| HuMax-CD4 (zanolimumab) |
Cutaneous T Cell lymphoma (CTCL) | Phase III | |
| Non-cutaneous T Cell lymphoma (NCTCL) | Phase II (completed) | ||
| HuMax-CD20 (ofatumumab) |
Chronic lymphocytic leukemia (CLL) | Phase III | GSK |
| Non-Hodgkin’s lymphoma (NHL) | Phase III | ||
| Rheumatoid Arthritis (RA) | Phase III | ||
| Diffuse large B cell lymphoma (DLBCL) | Phase II | ||
| HuMax-EGFr (zalutumumab) |
Head and neck cancer | Phase III | n/a |
| Non small cell lung cancer | Phase II | n/a | |
| HuMax-IL15 (AMG 714) |
Rheumatoid Arthritis (RA) | Phase II (completed) | Amgen |
| Psoriasis | Phase I | ||
| HuMax-IL8 | Palmoplantar pustulosis | Phase I/II (completed) | |
| HuMax-CD38 | Multiple myeloma | Phase I/II | |
| R1507 | Cancer | Phase I (completed) | Roche |
| Roche 2 | undisclosed | Phase I | Roche |
| Roche 3 | undisclosed | Phase I | Roche |
| Roche 4 | Asthma | Phase I | Roche |
| HuMax-HepC | Hepatitis C | pre-clinical | Connex GmbH and INSERM |
| HuMax-TAC | Organ transplant rejection | Pre-clinical |
[edit] References
- ^ a b c Annual Report 2007. Genmab A/S (31 March 2008). Retrieved on 2008-05-07.
- ^ Company Profile from the Genmab website
- ^ Genmab.com / Products in Development
[edit] External links
|
|||||
 |
This corporation or company article is a stub. You can help Wikipedia by expanding it. |
